Pendergrass J Cara, Targum Steven D, Harrison John E
Drs. Pendergrass and Targum are with Bracket Global and Clintara LLC, A Bracket Company, in Boston, Massachusetts.
Dr. Harrison is with the Alzheimer's Center and Department of Neurology, Neuroscience Campus Amsterdam, VU University Medical Center in Amsterdam, Netherlands; Institute of Psychiatry, Psychology, and Neuroscience (IoPPN), King's College London, United Kingdom; and Metis Cognition Ltd, Park House, Kilmington Common in Wiltshire, United Kingdom.
Innov Clin Neurosci. 2018 Feb 1;15(1-2):36-44.
This brief review explores the areas of cognitive impairment that have been observed in cancer patients and survivors, the cognitive assessment tools used, and the management of the observed cognitive changes. Cognitive changes and impairment observed in patients with cancer and those in remission can be related to the direct effects of cancer itself, nonspecific factors or comorbid conditions that are independent of the actual disease, and/or the treatments or combination of treatments administered. Attention, memory, and executive functioning are the most frequently identified cognitive domains impacted by cancer. However, the prevalence and extent of impairment remains largely unknown due to marked differences in methodology, definitions of cognitive impairment, and the assessment measures used. Assessment of cognitive functioning is an important and necessary part of a comprehensive oncological care plan. Research is needed to establish a better understanding of cognitive changes and impairments associated with cancer so that optimal patient outcomes can be achieved.
本简要综述探讨了在癌症患者及其幸存者中观察到的认知障碍领域、所使用的认知评估工具以及对所观察到的认知变化的管理。在癌症患者及其缓解期患者中观察到的认知变化和障碍可能与癌症本身的直接影响、与实际疾病无关的非特异性因素或合并症,以及/或者所给予的治疗或联合治疗有关。注意力、记忆力和执行功能是受癌症影响最常被识别出的认知领域。然而,由于方法、认知障碍的定义以及所使用的评估措施存在显著差异,障碍的患病率和程度在很大程度上仍不清楚。认知功能评估是综合肿瘤护理计划的重要且必要组成部分。需要开展研究以更好地了解与癌症相关的认知变化和障碍,从而实现最佳的患者治疗效果。